Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

Rang in Aktien #4650
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aktienkurs
$69.68
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$3.26B
Veränderung (1 Tag)
2.36%
Veränderung (1 Jahr)
-2.13%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)

Kategorie

Healthcare
Dividendenrendite-Verlauf für Tarsus Pharmaceuticals, Inc. (TARS)
Dividendenrendite (TTM) von Tarsus Pharmaceuticals, Inc. (Aktienkürzel: TARS) zum 2023-12-31: 0.00%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Tarsus Pharmaceuticals, Inc. (TARS) von 2018 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL